Future Tech
What’s in a name? Moderna’s “vaccine” vs. “therapy” dilemma
Moderna weighs rebranding mRNA vaccines as individual treatments to bypass public health polarization.
Is it the Department of Defense or the Department of War? The Gulf of Mexico or the Gulf of America? A vaccine—or an “individualized neoantigen treatment”? That’s the Trump-era vocabulary paradox facing Moderna, the covid-19 shot maker whose plans for next-generation mRNA vaccine...
MTR
MIT Technology Review
Source
MIT Technology ReviewRead the full story at MIT Technology Review

AI Analysis
Generated insight by OnAirToday AI
The shift in terminology from vaccine to therapeutic highlights how companies are rebranding mRNA technology to navigate politically charged skepticism. This linguistic pivot attempts to distance future life-saving treatments from the polarization surrounding COVID-19 immunization efforts.
Powered by AI • Not a substitute for human analysisMore Insights →
Share
Comments
Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.